November 2, 2008 Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is holding its Annual General Meeting for shareholders at 10.00 am this morning. At the meeting, the Chairman David Cleevely will make the following statement.
“I am pleased to report that trading for the 2009 financial year has started well and the Company has traded ahead of our expectations for the first four months of the year. Demand for our products has been strong and we continue to see growth across all regions. Trading has also benefitted from the weakness in sterling.
“As shareholders will appreciate, the threat of global recession and the volatility in the currency markets represent major risks for all businesses including our own. We believe however the demand from centrally funded research will provide significant resilience for our revenues. Overall, your board remains cautiously optimistic for the remainder of our financial year.”
